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Abstract
Background: Acute kidney injury (AKI) is common and often leads to significant morbidity and/or death. The
development of AKI, or complications associated with it, may be due to use of certain medications in at-risk
patients experiencing an intercurrent illness. Implicated drugs include diuretics, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers/direct renin inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs),
metformin and sulfonylureas. Expert consensus opinion (and clinical guidelines) recommend considering
discontinuation of diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/direct renin
inhibitors, NSAIDs, metformin and sulfonylureas in the event of an intercurrent illness to prevent AKI onset or
reduce severity or complications. However, the evidence base for these recommendations is very limited. This
systematic review aims to address the available evidence for the temporary discontinuation of diuretics, ACE
inhibitors, angiotensin receptor blockers, direct renin inhibitors, non-steroidal anti-inflammatories and metformin
and sulfonylureas for those at risk of AKI or with newly diagnosed AKI.
Methods/Design: Randomised controlled trials; non-randomised trials; cohort studies; case-control studies;
interrupted time series studies; and before-and-after studies featuring adults aged 18 and over in any setting
currently taking diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/direct renin
inhibitors, NSAIDs and metformin; experiencing an intercurrent illness; or undergoing a radiological/surgical
procedure (planned or unplanned) will be searched for. Relevant trial registers and systematic review databases will
be searched. Systematic reviews will be assessed for methodological quality using the ROBIS tool, trials will be
assessed using the Cochrane risk of bias tool, and observational studies will be assessed using the ACROBAT-NRS
tool. If sufficient studies assessing similar populations, study type, settings and outcomes are found, then a formal
meta-analysis will be performed to estimate summary measures of effect. If not, a narrative synthesis will be
adopted.
Discussion: This review will synthesise evidence for the efficacy of discontinuing diuretics, angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers/direct renin inhibitors, NSAIDs, metformin or sulfonylureas to
prevent or delay onset of AKI or associated complications. Results will provide guidance on efficacy and safety of
this strategy and potentially help to develop an intervention to test the best mechanism of guiding medication
discontinuation in at-risk populations.
Systematic review registration: PROSPERO CRD42015023210
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Background
Acute kidney injury (AKI) is a comparatively recent
term describing a sudden reduction in renal excretory
function. The term was introduced because of a lack
of agreement about what compromised ‘acute renal
failure’, with some definitions only including the re-
quirement for renal replacement therapy. The causes
of AKI can be divided into three groups: pre-renal,
such as low blood pressure; intrinsic renal, commonly
the result of prolonged sepsis or hypotension but also
resulting from immune conditions affecting the kid-
ney; and post-renal, caused by partial or complete ob-
struction to the flow of urine from the kidneys [1].
There are a number of key risk factors for AKI, in-
cluding the following: existing chronic kidney disease
(CKD), aged >65 years, cardiac failure, liver disease,
diabetes mellitus, use of nephrotoxic drugs such as
non-steroidal anti-inflammatories (NSAIDs) and ami-
noglycosides, hypotension (compared to baseline
blood pressure) and sepsis, neurological or cognitive
impairment or disability, or prior urological obstruc-
tion [1, 2]. An episode of AKI may be triggered by an
intercurrent illness, such as diarrhoea and vomiting,
influenza, other viruses, urinary tract infections, re-
spiratory tract infections, skin infections and hypovol-
aemia from any cause in those most at risk [1, 3].
The pooled incidence rate of AKI globally is 21.6 % in
adults [4], and AKI is predicted to feature in 1–7 % of
hospital admissions [1, 3, 5–7]. The morbidity and mor-
tality rates associated with an episode of AKI (in hospital
and after discharge) are high [6, 8–10]. Coca et al.’s sys-
tematic review reports that the incidence of CKD and
end-stage kidney disease (ESKD) after an AKI episode is
7.8 and 4.9/100 patient-years, respectively, and that AKI
is associated with long-term mortality [10].
Pannu and colleagues review the potentially harmful
biochemical effects of medications that are administered
as part of the routine care of critical illnesses in hospital
settings and conclude that many, such as angiotensin-
converting enzyme (ACE) inhibitors and NSAIDS, could
be detrimental to kidney function [9]. Medication-
induced episodes of kidney problems are increasingly
prevalent and indeed doubled between 1999 and 2009 in
the UK [11]. Commonly prescribed medications
including diuretics, ACE inhibitors/angiotensin receptor
blockers/direct renin inhibitors, NSAIDs, metformin and
sulfonylureas have been associated with AKI (and related
complications) in a variety of settings [12–30]. The inci-
dence of AKI is higher amongst patients who have mul-
tiple comorbidities and who are taking combinations of
drugs which may interact to enhance the physiological
insult underlying AKI [31].
Expert consensus statements and clinical guidelines
have recommended that clinicians temporarily withhold
potentially harmful medications for high-risk patients
when they develop an intercurrent illness to reduce risk
of AKI [1–3]. Other interventions have gone further by
suggesting that patients stop the medications when they
become unwell [32]. However, there is surprisingly little
evidence to support these recommendations. The
National Institute for Health and Clinical Excellence
(NICE) guidelines issued in 2013 found no studies which
evaluate the efficacy of medication discontinuation dur-
ing an intercurrent illness in terms of preventing onset
or harm from AKI [2]. There is growing concern regard-
ing the overall risks and benefits of the sick day rules
approach [33]. Such advice could lead to an increase in
complications from the conditions which the drugs are
prescribed such as heart failure and hypertension.
NSAIDs are recommended for pain control, especially
for osteoarthritis pain in older adults [34]; cessation of
NSAIDs may result in a marked reduction in mobility
and make the difference between a person coping at
home or not. In addition, it is suggested that continuing
some of these drugs will have renal and cardiac benefits,
even in the presence of AKI, at least in some patients.
ACE inhibitors and angiotensin receptor blockers/direct
renin inhibitors, for instance, preserve tubular blood
flow and may prevent the tubular injury that charac-
terises the transition from reversible pre-renal AKI to
established, intrinsic renal AKI, which has a poorer
prognosis [35].
Therefore, the overall objective of this review is to as-
sess the available evidence for the temporary discontinu-
ation of diuretics, ACE inhibitors, angiotensin receptor
blockers, direct renin inhibitors, non-steroidal anti-
inflammatories, metformin and sulfonylureas in adults
in primary and secondary care at risk of AKI or with
newly diagnosed AKI as a result of an intercurrent ill-
ness or a radiological/surgical procedure (planned or un-
planned). To address this objective, we will answer the
following review questions:
1. What are the effects of temporary discontinuation of
diuretics, angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers/direct renin inhibitors,
NSAIDs, metformin and sulfonylureas in those at
risk of AKI?
2. What are the effects of the temporary discontinuation
of diuretics, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers/direct
renin inhibitors, NSAIDs, metformin and sulfonyl-
ureas for the progression of AKI across AKI
severity categories?
3. What are the adverse effects associated with
stopping diuretics, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers/direct renin
inhibitors, NSAIDs, metformin and sulfonylureas?
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4. What is the effectiveness of interventions to
encourage stopping of diuretics, angiotensin-
converting enzyme inhibitors/angiotensin receptor
blockers/direct renin inhibitors, NSAIDs, metformin
and sulfonylureas?
Methods/Design
Systematic review methods will follow the principles out-
lined in the Centre for Reviews and Dissemination (CRD)
guidance for undertaking reviews in health care [36] and
the Cochrane Handbook [37]. The protocol is registered
on the PROSPERO database (CRD42015023210). The re-
view will be reported according to the PRISMA guidelines
[38, 39]. This protocol follows the PRISMA-P reporting
guidelines [40].
Eligibility criteria
Studies that fulfil the following criteria will be eligible
for inclusion:
Types of studies
The following types of studies will be included: rando-
mised controlled trials, non-randomised trials, cohort
studies, case-control studies, interrupted time series stud-
ies, before-and-after studies. If high-quality systematic re-
views are identified that fulfil all inclusion criteria for the
review, then these will be eligible for inclusion. We will in-
clude the systematic review if it includes all relevant stud-
ies for a single research question; if additional studies fulfil
our inclusion criteria, then the original review will be used
only as a source of relevant studies.
Participants
Only studies conducted in humans will be sought. Eligible
participants will be adults aged 18 and over in any setting
(e.g. community, GP surgery, hospital) currently taking di-
uretics, ACE inhibitors, angiotensin receptor blockers, dir-
ect renin inhibitors, non-steroidal anti-inflammatories,
metformin or sulfonylureas; experiencing an intercurrent
illness; or undergoing a radiological/surgical procedure
(planned or unplanned).
Interventions
Temporary discontinuation of diuretics, angiotensin-
converting-enzyme inhibitors/ angiotensin receptor
blockers / direct renin inhibitors, NSAIDs, metformin
and sulfonylureas as a result of a specific intervention
or for any other reason. Eligible comparator interven-
tions (if present) will be placebo, no treatment or
usual care.
Outcomes
The review will be restricted to studies that report some
measure of kidney function. We anticipate that other
relevant outcomes will include all-cause mortality, car-
diac events, diabetic events and pain-related outcomes
(pain severity, use of GP services or admission to hos-
pital relating to NSAID withdrawal).
Search strategy
Attempts will be made to identify relevant studies on tem-
porarily discontinuing diuretics, angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers/direct
renin inhibitors, NSAIDs, metformin and sulfonylureas.
Search methods will meet best practice standards in sys-
tematic reviews [36, 37]. The search strategies will be de-
veloped specifically for each database and the keywords
adapted according to the configuration of each database.
Searches will not be limited by language, date or publica-
tion status (unpublished or published). Searches will be
performed in multiple databases from inception to
present, including Embase (OvidSP), Medline (OvidSP),
Medline In-Process Citations & Daily Update (OvidSP),
PsycINFO (OvidSP), BIOSIS Citation Index (Web of
Science), CINAHL (Cumulative Index to Nursing and
Allied Health Literature) (EBSCO), Science Citation Index
(SCI) (Web of Science) and Cochrane Central Register of
Controlled Trials (CENTRAL) (Wiley).
Supplementary searches will be undertaken to identify
grey literature, completed and ongoing trials, in resources
such as NIH ClinicalTrials.gov (http://www.clinical
trials.gov), metaRegister of Controlled Trials (http://
www.controlled-trials.com) and WHO International
Clinical Trials Registry Platform (ICTRP) (http://
www.who.int/ictrp/en); relevant guidelines (i.e. NICE
in the UK) regarding management of AKI; and refer-
ences of published articles found in the search. An
example of the search strategy is presented in
Additional file 1.
Identified references will be downloaded into EndNote
X7 software for further assessment and handling. Rigorous
records are maintained as part of the searching process.
Individual records within the EndNote reference libraries
will be tagged with search information, such as searcher,
date searched, database host, database searched, strategy
name and iteration, theme, or search question. This will
enable the information specialist to track the origin of
each individual database record and its progress through
the screening and review process. A review-specific access
database will be used to manage screening and data
extraction.
Selection of studies
Two reviewers will independently screen the titles and
abstracts of all reports identified by searches, and any
discrepancies will be discussed and resolved by consen-
sus. Full copies of all studies deemed potentially relevant
will be obtained, and the same two reviewers will
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independently assess these for inclusion; any disagree-
ments will be resolved by consensus.
Data extraction
Data extraction will be carried out using standard data ex-
traction forms designed specifically for this review. Data
will be extracted by one reviewer, using a piloted, standard
data extraction form, and checked by a second reviewer;
any disagreements will be resolved by consensus. Data will
be extracted on the following: participant characteristics,
study design, inclusion and exclusion criteria, details of
intervention (if applicable—potentially including an out-
line of the characteristics of the interventions in terms of
the (1) format and content of any ‘sick day rules’ advice
and (2) whether part of a wider package of care, i.e. in the
context of other AKI/kidney health initiatives), details of
outcomes assessed (primary and other outcome measures)
and results. If, during the course of the review, outcome
measures commonly reported in studies are found these
will be included and documented [40].
Quality assessment
Systematic reviews will be assessed for risk of bias using
the ROBIS tool [41]: this tool’s aims include domains
covering study eligibility criteria, identification and se-
lection of studies, data collection and study appraisal,
synthesis and findings, and interpretation. Trials will be
assessed for methodological quality using the Cochrane
risk of bias tool [37]. This includes items covering selec-
tion bias (random sequence generation and allocation
concealment), performance bias (participant blinding),
detection bias (blinding of outcome assessors), attrition
bias (incomplete outcome data) and reporting bias (se-
lective reporting). There is also an additional field for
other sources of bias. We believe that all important con-
cerns about bias are included in the other domains in
the tool and so no further domains will be added. We
will use the new ACROBAT-NRS tool to assess the risk
of bias in observational studies [42]. It includes domains
covering bias due to confounding, bias in the selection
of participants into the study, bias due to departures
from intended interventions, bias due to missing data,
bias in taking measurements and bias in the selection of
the reported result. For all tools, if at least one of the do-
mains is rated as ‘high’, the study will be considered at
high risk of bias; if all domains are judged as ‘low’, the
trial will be considered at low risk of bias; otherwise, the
trial will be considered at ‘unclear’ risk of bias. The risk
of bias assessment will be conducted as part of the data
extraction process.
Data synthesis
A narrative summary of the included studies will be pre-
sented. This will include a summary of the characteristics
(e.g. study design, intervention (if applicable), population
size, geographical location, settings (community, hospital
or other healthcare settings), year, baseline population
characteristics and outcome definition). If data are consid-
ered too heterogeneous to pool, or not reported in a for-
mat suitable for pooling (e.g. data reported as medians),
then we will employ a narrative synthesis. This will involve
the use of descriptive text and tables to summarise data in
order to allow the reader to consider outcomes in the light
of differences in study designs and potential sources of
bias for each of the studies being reviewed. This involves
organising the studies by (as appropriate) population, out-
comes assessed, type of study and study settings; summar-
ising the results of the studies, summarising the range and
size of the associations these studies report; and describing
the most important characteristics of the included studies.
A detailed commentary on the major methodological
problems or biases that affected the studies will also be in-
cluded, together with a description of how this has af-
fected the individual study results.
If sufficient studies assessing similar populations, study
type, settings and outcomes are found, then a formal
meta-analysis will be used to estimate summary measures
of effect. For dichotomous data, we will calculate the rela-
tive risk (RR) for each study with the associated 95 % con-
fidence intervals. Continuous data will be analysed as the
mean difference between groups and associated 95 % con-
fidence intervals. For multi-arm studies, we will analyse
each intervention arm compared to the control group
separately.
We anticipate that systematic differences between stud-
ies (heterogeneity) will be likely. Therefore, the random ef-
fects model will be used to calculate summary estimates.
Heterogeneity will be investigated visually using forest
plots and statistically using the I2 and Q statistics [43].
Heterogeneity will be formally investigated using meta-
regression analyses, where sufficient data are available. We
anticipate that the effects of the following variables will be
investigated: methodological quality of the primary stud-
ies, how the advice or decision to discontinue medications
was administered and length of medication discontinu-
ation, age, sex, and comorbidities. Other variables consid-
ered relevant on further examination of the literature or
input from clinical experts may also be considered. The
coefficient describing the effect of each variable on the
outcome will be modelled, using a random effects model.
If appropriate, small-study effects (publication bias)
will be assessed using a modified linear regression test
for funnel plot asymmetry as recommended where there
are sufficient numbers of trials (i.e. six trials) [44].
Confidence in cumulative evidence
We will consider using the GRADE guidelines [45] to
help us evaluate the cumulative quality of the evidence
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reported in this review for risk of bias, publication bias,
imprecision, inconsistency, indirectness and magnitude
of effect.
Discussion
Diuretics, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, direct renin inhibitors,
NSAIDs, metformin and sulfonylureas in at-risk patients
experiencing an intercurrent illness are extremely com-
monly prescribed, and expert consensus (subsequently
incorporated into clinical guidelines) recommends the
discontinuation of these medications for individuals at
risk of AKI during an intercurrent illness. The benefit
from such advice is however unproven with scant
evidence regarding the benefits and potential harms that
discontinuation may confer. An up-to-date systematic
review of the evidence on discontinuing medications is
warranted. This review will provide evidence on the
effectiveness and safety of discontinuing diuretics,
angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers/direct renin inhibitors, NSAIDs, met-
formin and sulfonylureas in relation to AKI. We antici-
pate that the findings will aid healthcare practitioners
and policymakers in developing recommendations re-
garding advice on temporary drug cessation in patients
at risk of AKI. Furthermore, the findings will benefit re-
searchers by highlighting future research directions
through the identification of gaps in knowledge and
shortcomings of the existing evidence base.
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